Progress in DNA-based heterologous prime-boost immunization strategies for malaria - PubMed

Review

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

Anne C Moore et al. Immunol Rev. 2004 Jun.

Abstract

An effective vaccine against malaria is urgently required to relieve the immense human suffering and mortality caused by this parasite. A successful subunit vaccine against the liver stage of malaria will require the induction of high levels of protective T cells. Despite success in small animal models, DNA vaccines fail to induce strong cellular immune responses in humans. However, DNA vaccines can induce a T-cell response that can be strongly boosted by recombinant viral vectors. We have evaluated this heterologous prime-boost approach using the Plasmodium berghei mouse model for immunogenicity and protective efficacy against malaria challenge using combinations of plasmid DNA, recombinant modified vaccinia virus Ankara, fowlpox virus, and non-replicating adenovirus. We have proceeded to test immunogenicity and efficacy of successful heterologous prime-boost vaccines in phase I/IIa trials in malaria naïve subjects in the UK and in semi-immune individuals in The Gambia. In these clinical trials, remarkably high levels of effector T-cell responses have been induced and significant protection documented in a human sporozoite challenge model. We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans.

Similar articles

• DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.

  Hill AV, Reece W, Gothard P, Moorthy V, Roberts M, Flanagan K, Plebanski M, Hannan C, Hu JT, Anderson R, Degano P, Schneider J, Prieur E, Sheu E, Gilbert SC. Hill AV, et al. Dev Biol (Basel). 2000;104:171-9. Dev Biol (Basel). 2000. PMID: 11713817 Review.

• Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?

  Hoffman SL, Doolan DL. Hoffman SL, et al. Dev Biol (Basel). 2000;104:121-32. Dev Biol (Basel). 2000. PMID: 11713810

• Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.

  Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Reyes-Sandoval A, et al. Eur J Immunol. 2008 Mar;38(3):732-41. doi: 10.1002/eji.200737672. Eur J Immunol. 2008. PMID: 18266272

• Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

  McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. McConkey SJ, et al. Nat Med. 2003 Jun;9(6):729-35. doi: 10.1038/nm881. Epub 2003 May 25. Nat Med. 2003. PMID: 12766765 Clinical Trial.

• [Novel vaccines against M. tuberculosis].

  Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.

Cited by

• Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.

  Weiss WR, Kumar A, Jiang G, Williams J, Bostick A, Conteh S, Fryauff D, Aguiar J, Singh M, O'Hagan DT, Ulmer JB, Richie TL. Weiss WR, et al. PLoS One. 2007 Oct 24;2(10):e1063. doi: 10.1371/journal.pone.0001063. PLoS One. 2007. PMID: 17957247 Free PMC article.

• DNA vaccines: designing strategies against parasitic infections.

  Ivory C, Chadee K. Ivory C, et al. Genet Vaccines Ther. 2004 Dec 3;2(1):17. doi: 10.1186/1479-0556-2-17. Genet Vaccines Ther. 2004. PMID: 15579202 Free PMC article.

• Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

  Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr. Stewart VA, et al. Infect Immun. 2007 May;75(5):2283-90. doi: 10.1128/IAI.01879-06. Epub 2007 Feb 16. Infect Immun. 2007. PMID: 17307942 Free PMC article.

• Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.

  Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C, Schantz A, Geng D, Cawood P, Snyder LA. Marshall DJ, et al. Cancer Immunol Immunother. 2005 Nov;54(11):1082-94. doi: 10.1007/s00262-005-0687-0. Epub 2005 Jul 27. Cancer Immunol Immunother. 2005. PMID: 16047142 Free PMC article.

• Human Tumor Antigens and Cancer Immunotherapy.

  Vigneron N. Vigneron N. Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161423 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information